Achilles Therapeutics PLC ADR is a biotechnology business based in the US. Achilles Therapeutics PLC ADR shares (ACHL) are listed on the NASDAQ and all prices are listed in US Dollars. Achilles Therapeutics PLC ADR employs 234 staff and has a market cap (total outstanding shares value) of 0.00.
tastytrade
Finder Award
SoFi Invest
M1 Finance
| Latest market close | $1.02 |
|---|---|
| 52-week range | $0.75 - $3.45 |
| 50-day moving average | $0.93 |
| 200-day moving average | $1.54 |
| Wall St. target price | $8.80 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.84 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.0174 from 2023-06-02
| 1 week (2023-05-26) | 0.63% |
|---|---|
| 1 month (2023-05-05) | 14.64% |
| 3 months (2023-03-03) | -4.93% |
| 6 months (2022-12-05) | -40.50% |
| 1 year (2022-06-03) | -58.98% |
|---|---|
| 2 years (2021-06-04) | -91.93% |
| 3 years (2020-06-01) | N/A |
| 5 years (2018-06-01) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -17.7% |
| Return on equity TTM | -31.59% |
| Profit margin | 0% |
| Book value | $4.52 |
| Market capitalisation | $41.8 million |
TTM: trailing 12 months
We're not expecting Achilles Therapeutics PLC ADR to pay a dividend over the next 12 months.
Over the last 12 months, Achilles Therapeutics PLC ADR's shares have ranged in value from as little as $0.75 up to $3.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Achilles Therapeutics PLC ADR's is 0.9307. This would suggest that Achilles Therapeutics PLC ADR's shares are less volatile than average (for this exchange).
To put Achilles Therapeutics PLC ADR's beta into context you can compare it against those of similar companies.
Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom. .
Access remote advice, planning and portfolio management from this established financial services company.
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.
Steps to owning and managing UEC, with 24-hour and historical pricing before you buy.
Steps to owning and managing GROY, with 24-hour and historical pricing before you buy.
The best trading apps come with low fees and are easy to use.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.